For patients with cerebellar ALCL, whether sequential CAR-T cell therapy targeting CD30 and CD7 has long-term efficacy and whether it affects the patients’ immune function both require long-term follow-up to evaluate its effectiveness and safety. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.